NVO — NOVO NORDISK A S catalysts
Next verified catalyst
2026-12-14 — A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Livi · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-14 in 1mo
ESTIMATED |
READOUT
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help P
Phase 2 · Overweight, Obesity |
NVO NOVO NORDISK A S | NNC0662-0419 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-01-14 in 2mo
ESTIMATED |
READOUT
A Research Study on How Well Different Doses of the Medicine UBT251 Help People
Phase 2 · Overweight, Obesity |
NVO NOVO NORDISK A S | UBT251 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-01-25 in 3mo
ESTIMATED |
READOUT
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing
Phase 3 · Diabetes Mellitus, Type 1 |
NVO NOVO NORDISK A S | Insulin icodec, Insulin glargine, Insuli |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-01-29 in 3mo
ESTIMATED |
READOUT
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo
Phase 3 · Cardiovascular Risk, Acute Myocardial Infarction (AMI) |
NVO NOVO NORDISK A S | Ziltivekimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-03-01 in 4mo
ESTIMATED |
READOUT
A Research Study to Look at How Well CagriSema Helps People Living With Obesity
Phase 3 · Obesity |
NVO NOVO NORDISK A S | CagriSema (Cagrilintide B and Semaglutid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|